Zhuoran Yao
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 9
- Lung Cancer Research Studies 9
- CAR-T cell therapy research 4
- Immunology top 10%
- Immunotherapy and Immune Responses 2
-
- Lung Cancer Treatments and Mutations 4
-
- Neuroendocrine Tumor Research Advances 4
-
- Cancer therapeutics and mechanisms 3
-
- Myasthenia Gravis and Thymoma 2
- Journals
- International Journal of Radiation Oncology*Biology*Physics (2 papers)Modern Rheumatology (1 paper)Journal of Thoracic Oncology (1 paper)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Zhuoran Yao
16 papers receiving 810 citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Oncology 660
- Immunology 254
- Pulmonary and Respiratory Medicine 220
- Cancer Research 66
- Genetics 31
Countries citing papers authored by Zhuoran Yao
This map shows the geographic impact of Zhuoran Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhuoran Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhuoran Yao more than expected).
Fields of papers citing papers by Zhuoran Yao
This network shows the impact of papers produced by Zhuoran Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhuoran Yao. The network helps show where Zhuoran Yao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Zhuoran Yao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 2 | |
| 5 | 2025 | 1 | |
| 6 | 2024 | 7 | |
| 7 | 2023 | 23 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 4 | |
| 10 | 2022 | 63 | |
| 11 | 2022 | 1 | |
| 12 | Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysisbreakdown → | 2021 | 160 |
| 13 | 2021 | 0 | |
| 14 | 2021 | 10 | |
| 15 | 2020 | 249 | |
| 16 | 2020 | 57 | |
| 17 | 2020 | 3 | |
| 18 | 2019 | 177 | |
| 19 | 2018 | 58 |
About Zhuoran Yao
Zhuoran Yao is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 19 papers that have together received 817 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Research Studies (9 papers), Neuroendocrine Tumor Research Advances (4 papers), CAR-T cell therapy research (4 papers), Lung Cancer Treatments and Mutations (4 papers), Cancer therapeutics and mechanisms (3 papers), Myasthenia Gravis and Thymoma (2 papers) and Immunotherapy and Immune Responses (2 papers). The work is most often cited by research in Oncology (660 citations), Immunology (254 citations) and Pulmonary and Respiratory Medicine (220 citations). Zhuoran Yao has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Xiaoxiang Zhou, Xuan Zhang, Huaxia Yang, Naixin Liang, Fengchun Zhang, Xin Wang, Zhijie Wang, Hua Bai, Jie Wang and Kailun Fei. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Modern Rheumatology, Journal of Thoracic Oncology, Cell Reports Medicine and BMC Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.